Angion Biomedica Corp. (NASDAQ: ANGN) announces several strategic additions to its management team to support the future development and commercialization of ANG-3777
Angion Biomedica Corp. (NASDAQ: ANGN) presents late-breaking data on ANG-377 in delayed graft function at the American Society of Nephrology Kidney Week 2019.
Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage clinical biopharmaceutical company focused on kidney diseases and other acute organ injuries, announces the recent closing of a $35 million equity private placement.
Angion Biomedica Corp. (NASDAQ: ANGN) and Sinovant Sciences today announced a collaboration and license agreement for BB3, which is shown to have improved renal function post-transplant.
